contamination control – Pharma GMP

Periodic Review of CCS: Triggers, Scope and Outputs

digi — Sat, 22 Nov 2025 14:06:07 +0000

Periodic Review of CCS: Triggers, Scope and Outputs | Pharma GMP Guide Conducting a Periodic Review of Contamination Control Strategy (CCS): Step-by-Step Guide for Aseptic Manufacturing Ensuring the robustness and compliance of contamination control strategies (CCS) within aseptic manufacturing environments is critical for sterility assurance and patient safety. Regulatory authorities in the US, UK, and...

How Annex 1 Has Changed the Role of Microbiology in GMP Sites

digi — Sat, 22 Nov 2025 14:03:07 +0000

How Annex 1 Has Changed the Role of Microbiology in GMP Sites How Annex 1 Has Changed the Role of Microbiology in GMP Sites: A Step-by-Step Guide For pharmaceutical manufacturing sites engaged in aseptic manufacturing, understanding and complying with Annex 1 of the EU GMP guidelines has become paramount. The recent revision of Annex 1...

Aligning Contamination Control Strategy With Corporate Sterility Assurance Policies

digi — Sat, 22 Nov 2025 14:00:07 +0000

Aligning Contamination Control Strategy With Corporate Sterility Assurance Policies Step-by-Step Guide to Aligning Contamination Control Strategy With Corporate Sterility Assurance Policies The pharmaceutical industry’s sterile manufacturing sectors face increasingly stringent requirements to ensure product sterility and patient safety. A robust contamination control strategy (CCS) aligned with corporate sterility assurance policies is critical for compliance with...

Lessons From Major Contamination Events in Sterile Manufacturing

digi — Sat, 22 Nov 2025 13:57:07 +0000

Lessons From Major Contamination Events in Sterile Manufacturing Critical Lessons From Contamination Events in Aseptic Manufacturing and Annex 1 Compliance Ensuring sterility assurance during aseptic manufacturing remains a primary focus for pharmaceutical manufacturers globally. Over the past decades, multiple major contamination events have exposed vulnerabilities in contamination control systems, especially within Grade A and B...

Blueprint for an Inspection-Ready Annex 1 Contamination Control Strategy

digi — Sat, 22 Nov 2025 13:54:07 +0000

Blueprint for an Inspection-Ready Annex 1 Contamination Control Strategy Step-by-Step Guide to Designing an Inspection-Ready Annex 1 Contamination Control Strategy for Aseptic Manufacturing The revision and implementation of Annex 1 (EU GMP Volume 4, Chapter 1) have heightened expectations regarding contamination control strategies (CCS) in sterile pharmaceutical manufacturing. Pharmaceutical professionals across the US, UK, and...

Contamination Control in Single-Use Bioreactor and Manifold Set-Ups

digi — Sat, 22 Nov 2025 13:51:07 +0000

Contamination Control in Single-Use Bioreactor and Manifold Set-Ups Comprehensive Step-by-Step Guide to Contamination Control in Single-Use Bioreactor and Manifold Set-Ups Single-use bioreactors (SUBs) and manifold assemblies have revolutionized aseptic manufacturing by reducing cleaning demands and improving operational flexibility. However, their complex nature also necessitates stringent contamination control strategies to meet regulatory expectations and ensure sterility...

Managing Consumables (Wipes, Mops, Garments) in CCS and EM Programs

digi — Sat, 22 Nov 2025 13:48:07 +0000

Managing Consumables (Wipes, Mops, Garments) in CCS and EM Programs Comprehensive Guide: Managing Consumables in Contamination Control and Environmental Monitoring Programs In sterile pharmaceutical manufacturing environments, particularly in aseptic manufacturing, the proper management of consumables such as wipes, mops, and garments is critical for maintaining sterility assurance and compliance with Annex 1 requirements. This step-by-step...

Long-Term Trending of CCS Effectiveness: What to Track and How Often

digi — Sat, 22 Nov 2025 13:45:07 +0000

Long-Term Trending of CCS Effectiveness: What to Track and How Often Long-Term Trending of Contamination Control Strategy Effectiveness in Aseptic Manufacturing The pharmaceutical industry’s commitment to sterility assurance and contamination control is exemplified by stringent regulatory frameworks such as Annex 1 of the EU GMP guidelines. A critical component advancing manufacturing quality is the long-term...

Auditing Contamination Control Measures at CMOs and Fill–Finish Partners

digi — Sat, 22 Nov 2025 13:42:07 +0000

Auditing Contamination Control Measures at CMOs and Fill–Finish Partners Step-by-Step Guide to Auditing Contamination Control Measures in Aseptic Manufacturing at CMOs and Fill–Finish Partners Contract Manufacturing Organizations (CMOs) and fill–finish partners are integral to the sterile manufacturing supply chain. Ensuring robust contamination control systems at these external partners is paramount to maintaining sterility assurance and...

Using Third-Party Microbiology and EM Vendors Without Losing Control

digi — Sat, 22 Nov 2025 13:39:07 +0000

Using Third-Party Microbiology and EM Vendors Without Losing Control Effective Management of Third-Party Microbiology and Environmental Monitoring Vendors in Sterile Manufacturing Outsourcing microbiology and environmental monitoring (EM) services in aseptic manufacturing is a common practice within the pharmaceutical industry’s US, UK, and EU sectors. However, relying on third-party vendors for critical contamination control activities, especially...